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ABBREVIATIONS 
hs –CRP         - High sensitivity C- reactive protein 
LDL               - Low density lipoprotein 
HDL               - High density lipoprotein 
VLDL            - Very Low density lipoprotein 
TGL               - Triacylglycerol 
TC                 - Total Cholesterol 
VCAM          - Vascular cell adhesion Molecule 
ICAM            - Intra cellular Adhesion Molecule 
PECAM         - Platelet Endothelial Cell Adhesion Molecule 
MCP 1           - Monocyte chemotactic protein 1 
IL 1                - Interleukin 1 
IL 6                - Interleukin 6 
TNF α            - Tumour necrosis factor alpha 
PDGF             - Platelet derived growth factor 
TGF α            - Transforming growth factor alpha 
SAA              -  Serum Amyloid A 
AHA/ CDC   - American Heart Association/ Center for Disease Control 
AGE              - Advanced Glycated End Products 
RAGE            - Receptor for Advanced Glycated End Products 
 EDTA            - Ethylene Diamine Tetra Acetic Acid 
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INTRODUCTION 
 Diabetes mellitus is characterized by increased circulating plasma 
glucose concentrations associated with abnormal metabolism of 
carbohydrate, protein, fat and a variety of micro vascular and macro 
vascular complications. The prevalence of both type 1 and type 2 
diabetes has risen dramatically over the past two decades and is 
expected to rise phenomenally  in future due to decreased physical 
activity and obesity. It is predicted that type 2 diabetes will be increased 
to pandemic proportions in a few decades in Indian population. 
Cardiovascular disease is one of the leading cause of mortality and 
morbidity in patients with diabetes. It results from the sequlae of 
atherosclerotic coronary artery disease and the most common 
manifestations are acute myocardial infarction, angina, heart failure and 
sudden death. 
Atherosclerosis, the underlying cause of coronary artery disease 
starts early in life and progresses slowly usually for decades. It is not 
simply a disease of lipid deposition, but of an endothelial injury leading 
to endothelial dysfunction and local inflammatory changes which 
predispose to the formation of atherosclerotic plaque. These changes 
play a pivotal role in athero thrombotic disease progression. Diabetes is 
an independent risk factor for coronary artery disease and often is not 
associated with typical anginal symptoms, it becomes difficult to 
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diagnose the process of atherosclerosis at an early stage. The 
inflammatory changes found to be associated with atherosclerotic 
disease process, can be used for its identification. A well known marker 
of inflammation, namely C- reactive protein with the recent high 
sensitivity assays (hs- CRP) can detect inflammation associated with 
atherosclerosis at an early stage.  
          The  present  study is aimed at the evaluation of high sensitivity 
C- reactive protein as a marker  for   atherosclerosis.   High sensitivity 
C- reactive protein assay in patients with diabetes mellitus associated 
with and without coronary artery disease is performed and the results are 
correlated with lipid profile.    
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AIM OF THE STUDY 
The   study   is  aimed   at  estimating the levels of high sensitivity 
C – reactive protein in diabetes mellitus associated with and without 
coronary artery disease. 
 The study is also aimed at correlating the levels of high sensitivity 
C – reactive protein with the biochemical markers of atherosclerosis like 
total cholesterol, triacyl glycerol, high density lipoprotein, low density 
lipoprotein, very low density lipoprotein and the use of high sensitivity 
C – reactive protein as a predictor of atherosclerotic coronary artery 
disease in diabetes mellitus. 
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REVIEW OF LITERATURE 
          Atherosclerosis is a chronic immuno inflammatory, fibro-
proliferative disease, fueled by lipids, which affects primarily the intima 
of the medium sized and large sized arteries, resulting in intimal 
thickening, leading to luminal narrowing and inadequate blood supply.1  
 As the name implies, the mature atherosclerotic plaques consist of 
typically two main components. One is lipid rich and soft -athe’re is 
Greek for “gruel” or “porridge” and the other is collagen rich and hard- 
skleros is Greek for “hard”.                                                                                  
          At the beginning of twentieth century, cardiovascular disease 
accounted for less than 10 percent of all the deaths worldwide. But at the 
beginning of twenty first century, cardio vascular disease accounts for 
nearly half of all the deaths in the developed world and twenty five 
percent in the developing world. By 2020, it is predicted that 
cardiovascular disease will claim twenty five million lives annually and 
coronary heart disease will be the number one cause of death and 
disability, with every one in three deaths are due to coronary heart 
disease.2 
          Fuster V, 3 state that atherosclerosis, with superimposed 
thrombosis, `athero thrombosis´ is the leading cause of death and severe 
disability in affluent countries, and it will soon become pandemic, due 
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to increased incidence of obesity, insulin resistance and type 2 diabetes 
mellitus. 
RISK FACTORS FOR ATHEROSCLEROTIC CORONARY ARTERY 
DISEASE   
 Many prospective studies, like Framingham study established the 
coronary heart disease “risk” factors (i.e) factors that make the 
occurrence of the disease more probable.4 
 
       NON-MODIFIABLE             MODIFIABLE 
 
1. Increasing age 
2. Male gender 
3. Family history 
4. Genetic factors 
5. Personality (type A) 
 
 1. Hypertension 
 2. Diabetes 
 3. Smoking 
 4. Obesity 
 5. Hyper lipidemia 
 6. Sedentary life style 
 7. High carbohydrate       
    And trans unsaturated   
     Fat intake. 
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MODIFIABLE RISK FACTORS 
AGE 
            Age is a dominant influence. Atherosclerosis is not usually 
clinically evident until middle age. Between ages 40 and 60, the 
incidence of myocardial infarction increases five fold.                                
SEX 
        Males are more prone to atherosclerosis than females. The 
complications of atherosclerosis are uncommon in pre-menopausal 
women, unless they are predisposed by diabetes, hyper lipidemia or 
hypertension. 
 After menopause, the incidence of atherosclerosis increases due to 
a decrease in estrogen levels and the frequency of myocardial infarction 
equalizes by seventh to eighth decade of life. 
FAMILY HISTORY 
 The occurrence of premature atherosclerotic death in the family of 
age group less than 55 in a male first degree relative or less than 65 
years in a female first degree relative play a role in the atherosclerotic 
disease progression.5 
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GENETIC FACTORS 
 The familial predisposition to atherosclerosis and coronary 
ischemic disease is polygenic. It is also related to clustering of other risk 
factors, such as hypertension or diabetes or genetic derangements in 
lipoprotein metabolism. 
PERSONALITY 
 Type A personality, also known as Type A behaviour pattern, is a 
set of characteristics that includes being impatient, excessively time 
conscious, insecure about one’s status, highly competitive, hostile and 
aggressive, and incapable of relaxation. It was first described as an 
important risk factor in coronary disease in 1950’s by cardiologist 
Meyer Friedman and his coworkers. It is estimated that Type A 
behaviour doubles the risk of coronary heart disease in otherwise 
healthy men.6  
MODIFIABLE RISK FACTORS: 
HYPER TENSION 
Hypertension is a major risk factor for atherosclerosis at all ages. 
Both systolic and diastolic hypertension increases the risk. It is predicted 
that, there is a five fold risk of coronary heart disease when the blood 
pressure exceeds 140/90 mm Hg. 
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DIABETES 
The incidence of myocardial infarction is twice as high in 
diabetics as in non- diabetics. There is also an increased risk of stroke 
and atherosclerotic gangrene of lower extremities in diabetic patients. 
Uncontrolled and long standing diabetes induces hyper cholesterolemia 
and it markedly increases the premature atherosclerotic disease 
progression. 
SMOKING 
Cigarette smoking accelerates atherosclerosis and promotes acute 
ischemic events. The mechanisms are  
            1.  Hemodynamic stress (nicotine increases heart rate and 
transiently increases the blood pressure). 
            2.  Endothelial injury and dysfunction (nitric oxide release and 
resultant vasodilatation are impaired). 
3.  Development of atherogenic lipid profile (higher levels of 
Low density lipoprotein, more oxidized Low density lipoprotein, lower 
levels of High density lipoprotein). 
4.  Enhanced coagulability and induces chronic inflammatory 
state. 
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5.  Arrhythmogenesis. 
 6.  Relative hypoxemia because of effects of carbon 
monoxide.7  
OBESITY 
Body mass index ≥30 Kg/m2 is considered to be obesity and it 
plays a major role in atherosclerosis progression. Abdominal obesity 
rather than peripheral obesity (gluteal or subcutaneous) poses a high 
risk, by causing altered lipid levels and insulin resistance. 
HYPERLIPIDEMIA                                                                             
 Hyperlipidemia is a major risk factor for atherosclerosis. Presence 
of hypercholesterolemia is sufficient to initiate the disease process by 
producing an endothelial injury in the coronary arteries. The major 
component of total serum cholesterol associated with increased risk is 
Low density lipoprotein, which serves as a vehicle for the delivery of 
cholesterol to peripheral tissues.  
In contrast, high density lipoproteins act as “Good Cholesterol” 
by mobilizing the cholesterol from the developing atheroma and 
transport to the liver for excretion. 
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OTHER FACTORS 
Factors associated with increased risk of atherosclerosis include a 
sedentary life style with lack of exercise and poor eating habits (i.e) 
increased carbohydrate and trans unsaturated fat intake with decrease in 
fiber and vegetables. 
PATHOGENESIS OF ATHEROSCLEROSIS  
The concept of “response to injury” hypothesis considers 
atherosclerosis to be a chronic, inflammatory response of the arterial 
wall initiated by injury to the endothelium.8 Although the course of 
atherosclerotic disease progression is silent with a very long incubation 
period, the dreaded complications of this disease due to arterial lumen 
narrowing like myocardial infarction, angina, sudden cardiac death has 
led to focus much more attention, towards the pathogenesis of 
atherosclerosis. 
EVOLUTION OF ARTERIAL WALL CHANGES IN 
ATHEROSCLEROSIS 
 Chronic endothelial injury is caused by factors like 
hyperlipidemia, circulating derivatives of cigarette smoke, 
homocysteine, hemo dynamic shear stress, viruses and other infectious 
agents. This injury causes increased endothelial permeability, enhanced 
 11
leukocyte adhesion and alterations in expression of endothelial gene 
products.9               
          The normal endothelium will not bind to white blood cells. In 
contrast, the injured endothelium, expresses adhesion molecules, that 
have the capacity for binding to leukocytes. It includes the vascular cell 
adhesion molecule -1 (VCAM -1). It binds to monocytes and T- 
lymphocytes and paves way to the migration of these cells to intima of 
the coronary artery. These cells transform into macrophages and begin 
to engulf the oxidized low density lipoprotein, which is formed due to 
the oxidative stress induced by free radicals generated in macrophages 
and endothelial cells in the arterial wall.10 
 Macrophages produce interleukin-1(IL-1) and tumour necrosis 
factor (TNF) and chemokines such as monocyte chemotactic protein -
1(MCP-1) which increase the leukocyte adhesion on the endothelial cell. 
T-lymphocytes both CD4+ and CD8+ are also recruited to the intima 
and it induces cellular and humoral immune activation. T-cells cause 
release of inflammatory cytokines such as interferon- gamma and 
lymphotoxin, which in turn stimulate macrophages and smooth muscle 
cell replication and contribute to a dense extra cellular matrix 
characteristic of a more advanced atherosclerotic lesion.11              
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Several growth factors are reported to play a role in the 
proliferation of smooth muscle cells, which include platelet derived 
growth factor(PDGF), fibroblast growth factor, transforming growth 
factor- alpha. The smooth muscle cells also take up the modified lipids 
(oxidized lipids), and forms foam cells. Vascular smooth muscle cells 
synthesize extra cellular matrix molecules (mainly collagen) which 
stabilize the atherosclerotic plaque.12                                                                                   
          Hence this initial event of formation of intimal plaque is an 
aggregation of foam cells of macrophage and smooth muscle cell origin. 
With progression , the atheromatous lesion is modified by smooth 
muscle cell synthesized collagen and extracellular matrix molecules and 
formation of fibrous cap with retaining of central core of lipid laden 
cells and fatty debris. Inflammatory events make a significant 
contribution in the atherosclerotic disease progression. Inflammation 
disrupts the fibrous cap of atheromatous lesion by over expression of 
matrix metallo proteinases that can break down collagen and thinning of 
fibrous cap, leading to plaque rupture and fatal myocardial 
infarction.13,14 
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DIABETES AND ATHEROSCLEROTIC CORONARY ARTERY 
DISEASE 
 Vascular diseases are the major cause of morbidity and mortality 
in patients with diabetes mellitus. Diabetes causes micro vascular 
diseases such as nephropathy, neuropathy and retinopathy and macro 
vascular disease such as atherosclerosis. Atherosclerosis of the coronary, 
cerebral and peripheral arteries account for approximately 80 percent of 
mortality and 75 percent of hospitalizations in persons with diabetes.15 
The MULTIPLE RISK FACTOR INTERVENTION STUDY, has 
reported that men with diabetes had an absolute risk of death due to 
coronary artery disease three times higher than that in the non- diabetic 
even after adjustment for established risk factors.16 A FINNISH 
EPIDEMIOLOGICAL SURVEY compared the incidence of myocardial 
infarction in diabetic and non- diabetic populations. In this study, 
patients with diabetes without prior myocardial infarction had the same 
level of risk for subsequent acute coronary events as the non- diabetic 
persons with a history of previous myocardial infarction.17  
          The prevalence of atherosclerotic coronary artery disease is lower 
in pre- menopausal women when compared to their male counter part. 
This is due to the protective action of estrogen. But the incidence of 
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diabetes in these women, blunts the benefit of female gender for the risk 
of coronary artery disease.18 
Miettinen H et al19, have stated that diabetes increases the risk of 
death due to myocardial infarction in women more than men.  
PATHOPHYSIOLOGY OF DIABETIC VASCULAR DISEASE 
Diabetes is characterized by metabolic abnormalities including 
hyperglycemia, dyslipidemia and insulin resistance that disrupt the 
normal arterial function and will render arteries susceptible to 
atherosclerosis. 
PROLONGED HYPERGLYCEMIA AND PROTEIN GLYCATION 
Hyperglycemic episodes, in both type1 and type 2 diabetes cause 
non- enzymatic glycation of macromolecules like lipids and proteins. 
Glycated proteins can form structures known as advanced glycated end 
products (AGE). Glycation of low density lipoproteins, reduces their 
binding to the low density lipoprotein receptor and decrease their rate of 
their catabolism.20 Klen RL and Lyons TJ et al21, have demonstrated an 
increased uptake of glycated low density lipoprotein by macrophages. In 
addition, Duel PB and Oram JF22 have stated that glycated high density 
lipoprotein is cleared from the plasma at an enhanced rate, and its ability 
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to stimulate the cholesterol efflux from the atheroma is diminished 
compared to native high density lipoprotein. 
         Glycated proteins are immunogenic. It can produce an immune 
response and will contribute to the development and progression of 
macro vessel disease.23 Advanced glycated low density lipoprotein, are 
very much increased in diabetic subjects compared to non- diabetics. 
The glycated end products, mediate their biological effects through the 
surface receptors like receptor for advanced glycated and products 
(RAGE). The vascular cells, produce inflammatory cytokines, which 
impair endothelial dependent vasodilatation and increased endothelial 
expression of leukocyte adhesion molecules, like E- selectin, P- selectin, 
Intracellular adhesion molecule-1(ICAM-1), Vascular cell adhesion 
molecule-1(VCAM-1), GlyCAM-1, Platelet endothelial cell adhesion 
molecule(PECAM) which are implicated in atherosclerosis.24 
HYPERGLYCEMIA AND OXIDATIVE STRESS 
Hyperglycemia increases the production of reactive oxygen 
species in the vascular cells through enzymatic (protein kinase C and 
NADPH oxidases) and non enzymatic sources (formation of advanced 
glycated end products) 25. Normally, endothelium maintains the vascular 
homeostasis. Nitric oxide helps in this maintenance by its vasodilatory, 
anti-inflammatory and anti- thrombotic effects.  
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          Hyperglycemia decreases nitric oxide production from endothelial 
nitric oxide synthase and it also increases its degradation via generation 
of reactive oxygen species. As hyperglycemia induced oxidative stress 
increases, the cofactor for endothelial nitric oxide synthase 
tetrahydrobiopterin becomes oxidized. Oxidized tetrahydrobiopterin 
uncouples endothelial nitric oxide synthase, and causes this enzyme to 
produce superoxide anion instead of nitric oxide.26 
INSULIN RESISTANCE AND CARDIOVASCULAR DISEASE 
Insulin resistance is defined as “ resistance to effects of insulin on 
glucose uptake, metabolism and storage”. Insulin resistance leads to 
decreased uptake of glucose in muscle and adipose tissue and an 
inability of the hormone to suppress hepatic gluconeogenesis. The end 
result of all these, is the β cell failure leading to impaired glucose 
tolerance and diabetes mellitus. 
 
 
 
 
 
 17
 
 
 
 
 
 
 
 
 
  
 
 
Compensatory β-cell                                          Normoglycemia 
hyperplasia 
 
 
β-cell failure (early)                                              Impaired glucose                                
 tolerance 
                                                                                                       
 
 
β-cell failure (early)                                               Diabetes        
 
(Reproduced from Robbins and Cotran, Textbook on Pathologic 
basis of disease, 7th edition, page 1195)               
Thus insulin resistance leads to cardiovascular disease through 
hyperglycemia and related metabolic abnormalities. The occurrence of 
multiple metabolic abnormalities in an individual is termed as Insulin 
resistance syndrome or syndrome X or metabolic syndrome. 
                
 
Genetic 
predisposition 
Obesity, lifestyle 
factors 
Insulin resistance 
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                  COMPONENTS OF METABOLIC SYNDROME27 
                 VARIABLE                          DEFINING LEVELS 
                   Hyperglycemia                      > 110mg/dL 
                   Dyslipidemia                         HDL Cholesterol 
                                                                 Men <40mg/dL 
                                                                 Women <50mg/dL 
                                                                 Triglycerides >150mg/dL          
                     Obesity                               Waist circumference 
                                                                Men >40 inches                                                    
                                                                Women >35 inches 
                    Hypertension                      Blood pressure >130/85 mm Hg 
                    Age                                     Men >45years 
                                                                Women >55years 
Insulin resistance independently predicts the cardiovascular risk. 
Howard G et al28, have stated that insulin resistance positively correlates 
with atherosclerosis, as assessed by carotid intima media thickness. 
Lempianen P et al 29, state that severity of insulin resistance directly 
correlates with the incidence of myocardial infarction. 
DIABETIC DYSLIPIDEMIA 
The primary lipid disorders in diabetes are elevated triglycerides, 
decreased high density lipoprotein cholesterol and an increase in small 
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dense low density lipoproteins. Increased delivery of free fatty acids to 
the liver due to excess adipose tissue efflux and impaired skeletal 
muscle uptake increases hepatic production of very low density 
lipoprotein and cholesteryl ester synthesis. Over production of 
triacylglycerol rich lipoprotein and impaired clearance by lipoprotein 
lipase leads to hyper triglyceridemia in diabetes.30  
Free fatty acids also produce reactive oxygen species by 
activating intracellular enzymatic oxidant sources like protein kinase C, 
NADPH oxidase and endothelial nitric oxide syntheses.31 Triglyceride 
levels correlates inversely with high density lipoprotein levels as 
cholesteryl ester transfer protein mediates exchange of cholesterol from 
high density lipoprotein from very low density lipoprotein.30 Miller M, 
et al32 have noticed in their study of distribution of lipids in 8500 men 
with coronary artery disease, that elevated triglycerides and low high 
density lipoprotein is more common than elevated total and low density 
lipoprotein cholesterol in diabetic patients with coronary artery disease.  
In addition to the changes in the concentration of high density 
lipoprotein, functional defects occur in diabetic subjects, leading to 
decreased capacity to prevent low density lipoprotein oxidation, 
promoting atherogenesis.33 Increased concentrations of small, dense low 
density lipoprotein in diabetic persons results from abnormal cholesterol 
and triglyceride transfer between very low density lipoprotein and low 
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density lipoprotein, these molecules are proatherogenic. They bind to 
intimal proteoglycans, which enhances their retention in the intima, 
promoting the oxidative modification and are taken up by macrophages 
and smooth muscle cells.30    
OTHER PATHO PHYSIOLOGICAL CHANGES LEADING TO 
ATHEROSCLEROSIS 
Platelet abnormalities are common in diabetics, caused by 
activation of protein kinase C, decreased production of platelet derived 
nitric oxide, leading to oxidative stress.34 Diabetes impairs platelet 
calcium homeostasis and results in the abnormal platelet shape, 
aggregation and thromboxane formation. In addition, platelets in 
patients with diabetes have increased expression of adhesive 
glycoproteins. 35 
          Type 2 diabetes increases plasminogen activator inhibitor type 1 
levels, impairing fibrinolytic capacity in atherosclerotic lesions.36 
Diabetes also reduces the levels of endogenous anticoagulants.37 
Diabetes increase vascular smooth muscle growth and the migration of 
the smooth muscle cells into the atherosclerotic lesions. 
          Diabetes reduces the production of collagen, and increase the 
production of matrix metalloproteinases, there by decreasing the 
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stability of fibrous cap. This can lead to increased incidence of plaque 
rupture and thrombosis.38 
By all these mechanisms diabetes predisposes to accelerated 
process of atherosclerosis and increase the patient susceptibility to the 
thrombotic complications of atherosclerosis. 
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C – REACTIVE PROTEIN 
A   Sensitive   marker   of   inflammation   and tissue   damage,   
C –reactive protein has been named for its capacity to precipitate the 
somatic C- polysaccharide of streptococcus pneumoniae. It is the first 
among the acute phase protein to be described. 
          Originally, C –reactive protein was measured in clinical 
laboratories  to detect active infection and inflammation. The levels of 
C- reactive protein in these conditions varied from 3mg/L to 150mg/L. 
This wide range of C –reactive protein levels shows the lack of 
sensitivity in various infection and inflammation. It is not possible to 
apply such an assay for the determination of cardiovascular risk in 
apparently healthy men and women as the assay lacks sensitivity. 
           Immunoassays for C- reactive protein were developed with 
greater sensitivity. The development of these high sensitivity assays has 
gained importance in predicting the coronary artery disease by detecting 
the inflammatory changes caused by the pathogenesis of atherosclerosis. 
The  recent  method available is very sensitive for the measurement of 
C- reactive protein is capable of identifying a very narrow range 
between 0-3 mg/L.  
          So high sensitivity C- reactive protein measurements are very 
sensitive and can identify even minimal inflammatory reactions. It is 
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possible to use high sensitivity C- reactive protein for the identification 
of inflammatory changes associated with atherosclerosis.39 
STRUCTURE OF C- REACTIVE PROTEIN  
C- reactive protein belongs to the pentraxin (from the Greek word 
penta- five and ragos- berries)  family of calcium dependent ligand 
binding plasma proteins. The C- reactive protein molecule has a 
molecular weight of 115,135 Da and it is composed of five identical 
non- glycosylated polypeptide subunits of molecular weight 23,027Da, 
each containing 206 amino acid residues. 
          The protomers are non- covalently associated, with cyclic 
pentameric symmetry. Each protomer has the characteristic “lectin fold” 
composed of a two layered β sheet with flattened jelly roll topology. 
Two calcium ions are bound 4Å apart by protein side chains and this is 
the site of ligand binding. C- reactive protein binds with highest affinity 
to phosphocholine residues, and a variety of other autologous and 
extrinsic ligands, and aggregates or precipitates the molecular structures 
bearing these ligands. When C- reactive protein is ligand bound, it is 
recognized by C1q and potently activates the classical complement 
pathway, C3 the main adhesion molecule of the complement system and 
the terminal membrane attack complex C5- C9. Bound C- reactive 
protein also provides binding sites for factor H, there by regulates 
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alternative pathway amplification and C5 convertases. These may lead 
to cell lysis.   
The three dimensional structure of C reactive protein, shows the 
presence of deep, extended cleft in each protomer on the face of 
pentamer opposite to that containing phosphocholine binding site. This 
cleft is of functional importance. It is deep at its origin, but becomes 
shallow at the inner edge of the protomer , the shallow end of the pocket 
is bounded by the 112- 114 loop, residues 86- 92, the C- terminus of the 
pentraxin alpha helix 169-176, particularly tyrosine (175).This functions 
as a C1q binding site of C- reactive protein. Asp 112,Tyr 175 are 
important contact residues for C1q binding. Glu 88 influences the 
conformational change in C1q necessary for complement activation. 
Asn 158 and His 38 contribute to the geometry of the binding site.39, 40. 
SYNTHESIS AND CIRCULATION OF C- REACTIVE PROTEIN  
Atherosclerosis, and process of athero thrombotic events are 
inflammatory processes. This leads to expression of proinflammatory 
cytokines Interleukin- 1, which inturn expresses Interleukin- 6 which 
leads to increased expression of C-reactive protein gene, thereby the 
production of C- reactive protein is increased. 
In   healthy  young   adult   volunteer   blood  donors,   the  
median C-  reactive  protein concentration   is 0.8 mg/L. The synthesis 
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of C-reactive protein starts very rapidly after the initial stimulus, serum 
concentrations rise above 5mg/L by about 6 hours, and peak about 48 
hours. The plasma half life of C- reactive protein is 19 hours, and it is 
constant under all conditions. Hence the sole determinant of C- reactive 
protein concentration is the synthesis rate in the liver, which reflects 
directly the intensity of the pathological process. The circulating value 
of C- reactive protein, reflects the ongoing inflammation more 
accurately than other acute phase reactants. 
The C- reactive protein values show no diurnal variation and are 
unaffected by diet. Liver failure impairs C- reactive protein production. 
Its concentration is also independent of age, smoking, diabetes, 
hypertension and dyslipidemia. Use of oral contraceptives and post 
menopausal systemic hormone replacement therapy are associated with 
high C- reactive protein levels.41, 42 
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(Reproduced from James T. Willerson, Paul M. Ridker: 
Inflammation as a Cardiovascular risk factor and Vascular effect of 
Statins. Circulation 2004, 109: II2 –II10)                    
C- REACTIVE PROTEIN AND PATHOGENESIS OF 
ATHEROSCLEROSIS 
Numerous studies, have provided a positive correlation between 
elevated high sensitivity C-reactive protein levels and the underlying 
atherosclerotic disease process. The elevated levels of C- reactive 
protein, also predicts the future athero thrombotic events, including 
coronary events, stroke and progression of peripheral arterial disease. 
The predictive power for future cardiovascular disease, is stronger for 
Pro-inflammatory Risk Factors
(Oxidized LDL, infectious agents)
Vascular and extra vascular sources
Primary pro-inflammatory 
cytokines (IL1, TNF – α)
IL-6 Messenger Cytokine
CRP
SAA
Circulation
ICAM -1
Selectins
hsps, etc
Endothelium and other cells
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C- reactive protein than for Low density lipoprotein cholesterol. 
Physicians health study and Women health study showed that the 
predictive value of high sensitivity C- reactive protein was higher than 
the traditional biochemical risk marker for coronary heart disease like 
total cholesterol, high density lipoprotein and low density lipoprotein or 
novel markers like lipoprotein a, homocysteine, apolipoprotein A and 
apolipoprotein B.43 
          The reference values for low, moderate, high cardiovascular risk 
group has been set by AHA/CDC panel and are less than 1mg/L, 1mg/L 
to 3mg/L, greater than 3mg/L respectively. It has also recommended that 
high sensitivity C- reactive protein should be included in the global risk 
assessment of coronary heart disease in the primary prevention setting.44 
          Recent studies have proposed that C- reactive protein is not only a 
marker of inflammation in atherosclerosis, but an actual participant in 
the disease process. It is shown that C-reactive protein enhances 
expression of local endothelial cell surface adhesion molecules, 
monocytes chemotactic protein-1, endothelin-1, plasminogen activator 
inhibitor-1, reduce endothelial nitric oxide bioactivity and increase the 
tissue uptake of modified low density lipoprotein by binding to it. In 
addition, C- reactive protein once formed may activate complement, 
sustain inflammation and induce monocytes to produce Interleukin 6 
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and interleukin 7, that in turn induces C-reactive protein production. 
Thus C- reactive protein once formed can activate its own synthesis.45  
         With all these evidences, the present study is aimed at measuring 
C- reactive protein with the high sensitivity assays and correlates the 
values with traditional biochemical risk markers of atherosclerosis like 
total cholesterol, high density lipoprotein and low density lipoprotein. 
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MATERIALS AND METHODS 
The study was conducted after getting the approval from the 
ethical committee of Stanley medical college. Hundred subjects were 
chosen for the study. All of them were males of age group 45 years- 70 
years and an informed consent was obtained from all of them. 
Fifty subjects, who were diagnosed to be diabetic, as per criteria 
of American diabetes association and WHO 2004, with no evidence of 
atherosclerotic coronary artery disease in Electrocardiogram formed the 
control group. They were selected from the department of Diabetology, 
Stanley Medical College.   
          Fifty subjects, who were diagnosed to be diabetic, as per the 
criteria of American diabetes association and WHO 2004 and associated 
with evidence of atherosclerotic coronary artery disease in 
Electrocardiogram formed the case group and they were selected from 
the department of Cardiology, Stanley medical college. 
INCLUSION CRITERIA 
1)  Subjects diagnosed to be diabetic with any one of the 
following criteria in two occasions 
Symptoms of diabetes plus random plasma glucose concentration 
≥200 mg/dL.   (or) 
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          Fasting (defined as no caloric intake for at least 8 hours) plasma 
glucose ≥ 126 mg/dL.  (or) 
          Two hours plasma glucose ≥200 mg/dL during an oral glucose 
tolerance test. 
          2)  Presence of atherosclerotic coronary artery disease 
evidenced by Electrocardiogram changes like  
Abnormal ST-T wave changes (ST segment elevation or 
depression or deep symmetrical T wave inversion) and formation of new 
Q waves. 
EXCLUSION CRITERIA 
1)  Presence of hypertension, defined by resting systolic    
blood pressure > 140 mmHG and diastolic blood pressure > 90 mm HG. 
2)  Presence of Obesity, defined by body mass index more than 
30 kg/m2. 
3)  Presence of malignancy and concomitant systemic diseases 
like rheumatic disease, chronic liver disease, renal disorder and sepsis. 
4)  Critically ill patients, smokers and alcoholics. 
5)  Ongoing infectious diseases. 
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          6)  Having known thrombotic or bleeding disorders. 
7)  Persons on Statin therapy. 
BLOOD COLLECTION 
5mL of Blood samples were collected by vene puncture with 
strict aseptic precaution after an overnight fast for at least 12 -14 hours. 
1mL of the sample was aliquoted into a test tube containing EDTA and 
Sodium fluoride mixture (0.5mg+ 1mg). The sample was centrifuged 
and plasma separated and the analysis for glucose was done 
immediately. 
               Remaining 4 mL of the sample was allowed to clot and the 
serum was separated after centrifugation and the analysis of total 
cholesterol, triglycerides, high density lipoprotein was done 
immediately and 0.5 mL of serum was stored at -20 ْ C for analysis of 
high sensitivity C- reactive protein. 
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ESTIMATION OF PLASMA GLUCOSE 
The tests are performed in the reagent kit by GLUCOSE OXIDASE- 
PEROXIDASE METHOD. 
Principle 
        Glucose is oxidized by Glucose Oxidase (GOD) into gluconic acid 
and hydrogen peroxide. Hydrogen peroxide in the presence of 
Peroxidase (POD) oxidizes chromogen 4-amino antipyrine and phenolic 
compound to form a pink coloured compound.  
Glucose + O2                                               Gluconic acid +H2O2 
H2O2 +phenolic Compound +4-amino antipyrine 
                                                                      Pink Compound +H2O 
The intensity of the colour formed is proportional to the glucose 
concentration and is measured at 505nm. 
Reagents                                                                                                                             
Buffer/ Enzymes/ Chromogen                                                                                           
Phosphate buffer                        95 m mol/L 
4- amino antipyrine                    0.2 m mol/L 
 p- Hydroxy benzoic acid           5.9 m mol/ L 
Glucose Oxidase 
Peroxidase 
 33
 Glucose Oxidase                        ≥ 5000 U/L 
 Peroxidase                                 ≥ 5000 U/L 
Standard 
Glucose                     100mg/dL        
 
General system parameters        
Reaction type End point          
Reaction Slope Increasing 
Wavelength 505 nm 
Flow cell temperature 30 ْC 
Incubation 30 minutes /15 minutes 
      RT/ 30 ْC 
Sample volume 10µL 
Reagent volume 1000 µL 
Zero setting with Reagent blank 
Standard  100 mg/dL 
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Procedure 
 Blank Standard Test 
Reagent 1mL 1mL 1mL 
Standard -- 10 µL -- 
Sample -- -- 10 µL 
 
Mix well and incubate for 15 minutes.  
Calculation 
Abs. of sample    
Glucose (mg/dL) =     ----------------------   x  Concentration of the standard 
Abs. of Standard 
ESTIMATION OF TOTAL CHOLESTEROL 
The tests are performed in the reagent kit by ENZYMATIC 
CHOLESTEROL ESTERASE METHOD. 
Principle 
         The free cholesterol liberated from the cholesterol esters by 
cholesterol esterase is oxidized by cholesterol oxidase to cholestenone 
with the simultaneous production of hydrogen peroxide. The hydrogen 
peroxide reacts with 4- amino antipyrine and a phenolic compound in 
the presence of peroxidase to yield a red coloured complex.  
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Peroxidase 
Cholesterol esterase 
Quinone imine dye+H2O 
 
 
Cholesterol ester + H2O                                              Cholesterol + Fatty acid                              
                                                                               
Cholesterol + O2                                                         Cholestenone + H2O2 
H2O2 +4-aminoantipyrine +Phenolic Compound                   
 
 
The concentration of cholesterol in the sample is directly 
proportional to the intensity of the red coloured complex which is 
measured at 500 nm. 
Reagents 
Reagent 1 (Enzymes/ Chromogen) 
Cholesterol esterase                   ≥ 200 U/L 
Cholesterol oxidase                    ≥ 250 U/L 
Peroxidase                                  ≥ 1000U/L 
4- Amino antipyrine                   0.5 m mol/L 
Reagent 1A ( Buffer) 
Pipes buffer, pH 6.90                 50 m mol/L 
Phenol                                        24 m mol/L 
Cholesterol Oxidase 
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Sodium cholate                          0.5 m mol/L 
Standard: 
Cholesterol                                 200 mg/dL 
Reconstituted Reagent 
Dissolve the contents of one bottle of reagent 1 with one bottle of 
reagent 1A.       
General system parameters 
Reaction type End point          
Reaction Slope Increasing 
Wavelength 500 nm 
Flow cell temperature 30 
Incubation 5 minutes at 37 ْC
Sample volume 10µL 
Reagent volume 1000 µL 
Zero setting with Reagent blank 
Standard 200 mg/dL 
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Procedure 
 Blank Standard Test 
  Reagent   1mL    1mL 1mL 
 Standard    --    10 µL     -- 
 Sample    --      --   10 µL 
 
Incubate for 5 minutes at 37 ْC. 
Calculation  
        Abs. of Unknown    
Total Cholesterol ( mg/dL) =   --------------------------- x Concentration of Std. 
                                                     Abs. of Standard 
ESTIMATION OF TRIACYLGLYCEROL 
The tests are performed in the reagent kit by Enzymatic 
Colorimetric method. 
Principle  
          Lipoprotein lipase catalyzed hydrolysis of triglycerides yield 
glycerol which is phosphorylated  by Glycerol kinase using ATP to 
glycerophosphate  which upon oxidation yields dihydroxy acetone 
phosphate and hydrogen peroxide. The hydrogen peroxide is used to 
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Glycerol Kinase 
oxidize 4 amino antipyrine and N- Ethyl-N- Sulfopropyl-N-anisidine 
(ADPS) and water. 
Triacylglycerol+H20                      Glycerol +free fatty acids 
Glycerol+ATP                                Glycerol 1Phosphate +ADP 
Glycerol 1-Phosphate +O2                                       DAP +H2O2 
H2O2+4-Aminoantipyrine +DHBS                                Quinoneiminedye 
                                                                                            + H20   
DAP –Dihydroxy acetone phosphate 
DHBS – 3,5 Dichloro 2-hydroxy benzene sulfonate 
The intensity of the purple coloured complex formed during the 
reaction is directly proportional to the triacylglycerol concentration in 
the sample and it is measured at 546nm.  
Reagents 
Reagent 1 (Enzymes / Chromogen) 
Lipoprotein Lipase                          ≥ 1100 U/L 
Glycerol Kinase                               ≥ 800 U/L 
Glycerol -3 – phosphate oxidase     ≥ 5000 U/L 
Glycerol phosphate
    Oxidase 
Peroxidase 
Lipase 
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Peroxidase                                       ≥ 350 U/L 
4- Amino antipyrine                       0.7 m mol/L 
ATP                                                 0.3 m mol/L 
Reagent 1A (Buffer) 
Pipes buffer, pH 7.50                     50 m mol/L 
ADPS                                              1 m mol/L 
Magnesium salt                               15 m mol/L 
Standard 
Triacylglycerol                              200 mg/dL. 
Reconstituted Reagent 
Dissolve the contents of one bottle of reagent 1 with one bottle of 
reagent 1A. 
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General system parameters       
Reaction type End point          
Reaction Slope Increasing 
Wavelength 505 nm 
Flow cell temperature 30 ْC 
Incubation 5 minutes at 37 ْC
Sample volume 10µL 
Reagent volume 1000 µL 
Zero setting with Reagent blank 
Standard  200 mg/dL 
 
Procedure 
 Blank Standard Test 
  Reagent   1mL    1mL 1mL 
 Standard    --    10 µL     -- 
 Sample    --      --   10 µL 
 
Mix well and incubate for 5 minutes at 37 ْC. 
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Calculation 
            Abs. of sample   
Triacylglycerol (mg/dL)    =  ---------------------   x  Concentration of the Standard                                   
                                               Abs. of Standard 
ESTIMATION OF HIGH DENSITY LIPOPROTEIN: 
          The tests are performed in the reagent kit by 
PHOSPHOTUNGSTATE METHOD. 
Principle 
Chylomicrons, very low density lipoprotein, low density 
lipoprotein fractions in serum or plasma are separated from high density 
lipoprotein (HDL) by precipitating with phosphotungstic acid and 
magnesium chloride. After centrifugation, the cholesterol in the HDL 
fraction, which remains in the supernatant is assayed with enzymatic 
cholesterol method, using Cholesterol esterase, Peroxidase method. 
Reagents 
Reagent 1 (Enzymes/ Chromogen) 
Cholesterol esterase                   ≥ 200 U/L 
Cholesterol oxidase                    ≥ 250 U/L 
Peroxidase                                  ≥ 1000U/L 
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4- Amino antipyrine                   0.5 m mol/L 
Reagent 1A ( Buffer) 
Pipes buffer, pH 6.90                 50 m mol/L 
Phenol                                        24 m mol/L 
Sodium cholate                           0.5 m mol/L 
Reagent 2 (Precipitating Reagent) 
Phosphotungstic acid                   2.4 m mol/L 
Magnesium  Chloride                  39 m mol/L 
Standard 
HDL Cholesterol                        50 mg/dL 
Procedure 
1.  Precipitation 
dispense into centrifuge tubes. 
    Test 
Sample 200 µL
Precipitating reagent 200 µL
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Mix well. Centrifuge at 3500 – 4500 rpm for 10 minutes. Separate the 
clear supernatant immediately and determine the cholesterol content. 
General system parameters       
Reaction type End point          
Reaction Slope Increasing 
Wavelength 500 nm 
Flow cell temperature 30ْ 
Incubation 5 minutes at 37 ْC 
Sample volume(Supernatant) 20µL 
Reagent volume 1000 µL 
Zero setting with Reagent blank 
Standard  100 mg/dL 
 
Procedure 
 Blank Standard Test 
  Reagent   1mL    1mL 1mL 
 Standard    --    20 µL     -- 
 Sample    --      --   20 µL 
 
Mix well and incubate for 5 minutes at 37 ْC.  
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Calculation 
                                                       Abs. of sample   
HDL Cholesterol  (mg/dL)    =   ------------------------ x Concentration of standard  
                                                      Abs. of Standard 
 
CALCULATED PARAMETERS: 
Friedwald’s Formula: 
Triacylglycerol 
Very Low Density Lipoprotein:      --------------------- 
                                                                        5 
Low Density Lipoprotein: Total Cholesterol – HDL –   Triacylglycerol 
----------------------- 
                                                                                                5 
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ESTIMATION OF HIGH SENSITIVITY C -REACTIVE 
PROTEIN 
Particle enhanced Immunoturbidimetric test 
Principle 
The CRP – ultra sensitive assay is a quantitative turbidimetric test 
for the measurement of low levels of C- reactive protein in human serum 
or plasma. Latex particles coated with specific anti- human CRP are 
agglutinated when mixed with samples containing CRP. The 
agglutination causes an absorbance change, dependent upon the CRP 
contents of the patient sample that can be quantified by comparison 
from calibrator of known CRP concentration. 
Reagents Reagent 1 (Diluent) 
                  Tris buffer 20 m mol/L 
                  Sodium azide 0.95 g/L 
                  pH   8.2 
Reagent 2 (Latex reagent) 
                  Latex particles coated with goat IgG anti- human CRP 
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Sample : Clear serum sample 
Procedure                                                                                                                            
Dispense             Calibrator  Sample
Working reagent 1000 µL 1000 µL
Calibrator   10 µL    -- 
Sample     --     10 µL
 
Measure the absorbance at 540 nm after 10 seconds and after 4 
minutes of sample addition. The absorbance differences are calculated 
for each CRP calibrator and the values are plotted against the CRP 
concentration in a calibration curve. CRP Concentration in the sample is 
calculated by interpolation of the of the absorbance values in the 
calibration curve. 
Reference values :  0 - 3 mg/L. 
Absorbance of hs-CRP calibrators: 
Concentration of Standards(mg/L) Absorbance 
0.000 
0.585 
1.170 
2.925 
5.850 
   0.000 
   0.015 
   0.030 
   0.080 
   0.129 
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RESULTS AND STATISTICAL ANALYSIS 
              A total of 100 patients were included in the present study. Out 
of the 100, 50 were study group (Diabetes mellitus with Atherosclerotic 
coronary artery disease) and other 50 were controls (Diabetes mellitus 
without Atherosclerotic coronary artery disease). 
AGE DISTRIBUTION AMONG THE STUDY AND CONTROL 
GROUP 
              Male patients in the age group 45 years- 70 years were taken 
for the study. Both the Study and control group patients were age 
matched. The mean age of the study group is 54.94 and the mean age of 
the control group is 52.88. 
Table 1 
Group N Mean 
Standard
Deviation
Student independent t test 
Control 
Study 
50
50
52.88 
54.94 
6.08 
6.28 
                   t=1.67 
                  p=0.09 
         Not Significant 
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Qualitative variable (age) is given as frequency with their percentages. 
Table 2 
Control Study  
 N  %  N  % 
Chi Square test 
Age <50 
       51-60 
        >60 
Total      
19 
25 
6 
50 
61.3
45.5
42.9
50.0
12
30
8 
50
38.7
54.5
57.1
50.0
           p=0.31 
     Not Significant 
 
The Serum levels of total cholesterol, triacylglycerol, high density 
lipoprotein, hs- CRP were estimated for all the patients taken for the 
study. Low density lipoprotein and very low density lipoprotein values 
were calculated. The values obtained in both the study and control group 
are presented in the Master chart I and II. 
          Mean and Standard deviation were calculated for the Quantitative 
variables (total cholesterol, triacylglycerol, high density lipoprotein, low 
density lipoprotein and very low density lipoprotein, hs- CRP) in both 
study and control group. The values were analyzed using Student’s 
Independent `t´ test. The results are presented in tables 3-6. 
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          Correlation between hs –CRP and other variables were analyzed 
using Pearson’s correlation analysis. The results are presented in tables 
7& 8. 
           The Receiver Operating Characteristic (ROC) Curves are plotted 
for low density lipoprotein, LDL/HDL ratio, total Cholesterol/HDL ratio 
and hs- CRP and it is presented in figures 1-4. 
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COMPARISON OF THE BIOCHEMICAL PARAMETERS IN 
THE STUDY AND CONTROL GROUP: 
Table 3 
Parameter Group Mean Standard Deviation 
Student 
Independent  t 
test 
Plasma Glucose Control
Study 
120.66
125.50
37.98 
33.90 
t=0.67 
p=0.50 
Not Significant 
Total Cholesterol Control
Study 
178.84
190.42
42.91 
38.16 
t=1.42 
p=0.16 
Not Significant 
Triacylglycerol Control
Study 
128.90
158.76
66.39 
17.16 
t=2.08 
p=0.04 
Significant 
High density 
lipoprotein 
Control
Study 
38.08
33.30
9.27 
8.12 
t=2.74 
p=0.01 
Significant 
Low density 
lipoprotein 
Control
Study 
107.54
131.34
38.55 
34.39 
t=3.25 
p=0.05 
Significant 
Very Low density 
lipoprotein 
Control
Study 
25.68
29.78
13.28 
3.41 
t=2.01 
p=0.05 
Significant 
Total Cholesterol/ 
High density 
lipoprotein 
Control
Study 
4.94
5.91
1.43 
1.34 
t=3.49 
p=0.001 
Significant 
Low density 
Lipoprotein / High 
density lipoprotein 
Control
Study 
2.99
4.04
1.21 
1.14 
t=4.43 
p=0.001 
Significant 
High Sensitivity C- 
reactive protein 
Control
Study 
1.74
6.51
0.78 
1.02 
t=26.15 
p=0.001 
Significant 
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COMPARISON OF THE BIOCHEMICAL PARAMETERS IN 
AGE MATCHED STUDY AND CONTROL GROUP 
Table 4 
Age <50 years 
Parameter Group Mean Standard Deviation 
Student 
Independent t test 
Plasma Glucose Control
Study 
126.79
126.92
35.28 
25.09 
t=0.01 
p=0.99 
Not Significant 
Total Cholesterol Control
Study 
176.37
190.42
41.57 
32.25 
t=0.99 
p=0.33 
Not Significant 
Triacylglycerol Control
Study 
127.74
134.75
50.39 
22.02 
t=0.45 
p=0.65 
Not Significant 
High density 
lipoprotein 
Control
Study 
40.95
35.83
10.01 
8.11 
t=1.48 
p=0.15 
Not Significant 
Low density 
lipoprotein 
Control
Study 
104.58
129.09
45.38 
30.61 
t=1.64 
p=0.11 
Not Significant 
Very Low density 
lipoprotein 
Control
Study 
25.95
26.50
9.99 
4.40 
t=0.47 
p=0.64 
Not Significant 
Total Cholesterol/ 
High density 
lipoprotein 
Control
Study 
4.63
5.51
1.62 
1.44 
t=1.52 
p=0.14 
Not Significant 
Low density 
Lipoprotein / High 
density 
lipoprotein 
Control
Study 
2.81
3.55
1.48 
0.99 
t=1.51 
p=0.14 
Not Significant  
High Sensitivity C- 
reactive protein 
Control
Study 
1.55
7.05
0.61 
1.01 
t=18.96 
p=0.001 
Significant 
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COMPARISON OF THE BIOCHEMICAL PARAMETERS IN 
AGE MATCHED STUDY AND CONTROL GROUP 
Table 5 
Age 51-60 years 
Parameter Group Mean Standard Deviation 
Student 
Independent t test 
Plasma Glucose Control
Study 
116.80
124.07
43.17 
39.32 
t=0.65 
p=0.52 
Not Significant 
Total Cholesterol Control
Study 
179.84
183.17
46.82 
35.70 
t=0.29 
p=0.77 
Not Significant 
Triacylglycerol Control
Study 
125.72
163.43
79.98 
13.11 
t=0.45 
p=0.65 
Not Significant 
High density 
lipoprotein 
Control
Study 
35.76
31.70
8.76 
7.01 
t=2.58 
p=0.01 
Not Significant 
Low density 
lipoprotein 
Control
Study 
107.40
126.30
34.84 
33.27 
t=2.05 
p=0.04 
Significant 
Very Low density 
lipoprotein 
Control
Study 
25.56
32.13
16.07 
2.59 
t=2.49 
p=0.02 
 Significant 
Total Cholesterol/ 
High density 
lipoprotein 
Control
Study 
5.18
5.94
1.34 
1.26 
t=2.16 
p=0.04 
 Significant 
Low density 
Lipoprotein/ High 
density 
lipoprotein 
Control
Study 
3.11
4.10
1.08 
1.17 
t=3.23 
p=0.002 
Significant  
High Sensitivity C- 
reactive protein 
Control
Study 
1.86
6.34
0.91 
1.02 
t=17.03 
p=0.001 
Significant 
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COMPARISON OF THE BIOCHEMICAL PARAMETERS IN 
AGE MATCHED STUDY AND CONTROL GROUP 
Table 6 
Age >60 years 
Parameter Group Mean Standard 
Deviation 
Student 
Independent t test 
Plasma Glucose Control
Study 
117.33
128.75
21.92 
25.02 
t=0.88 
p=0.39 
Not Significant 
Total Cholesterol Control
Study 
182.50
217.63
35.42 
46.97 
t=1.53 
p=0.15 
Not Significant 
Triacylglycerol Control
Study 
132.00
142.75
33.86 
17.76 
t=0.77 
p=0.45 
Not Significant 
High density 
lipoprotein 
Control
Study 
38.67
35.50
7.36 
11.27 
t=0.59 
p=0.56 
Not Significant 
Low density 
lipoprotein 
Control
Study 
117.50
153.50
34.16 
39.28 
t=1.79 
p=0.01 
Significant 
Very Low density 
lipoprotein 
Control
Study 
26.63
28.63
6.80 
3.50 
t=0.82 
p=0.42 
Not Significant 
Total Cholesterol/ 
High density 
lipoprotein 
Control
Study 
4.79
6.44
1.00 
1.44 
t=2.38 
p=0.03 
Significant 
Low density 
Lipoprotein/ High 
density 
lipoprotein 
Control
Study 
3.06
4.53
0.80 
1.11 
t=2.71 
p=0.02 
Significant  
High Sensitivity C- 
reactive protein 
Control
Study 
1.90
6.35
0.66 
0.87 
t=10.37 
p=0.001 
Significant 
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PEARSON’S CORRELATION ANALYSIS: 
Table 7 
 Age TGL CHOL(T) HDL VLDL LDL hs CRP 
LDL/HDL ratio Vs        
t value 0.16 0.65 0.40 0.48 0.07 0.55 0.28 
p value 0.25 0.06 0.004 0.001 0.58 0.002 0.043 
Significance ns ns S S ns S S 
 
 
Table 8 
 Age TGL CHOL(T) HDL VLDL LDL LDL/HDL
hs CRP Vs        
t value 0.12 0.01 0.07 0.12 0.04 0.11 0.28 
p value 0.37 0.90 0.59 0.40 0.78 0.44 0.043 
Significance ns ns ns ns ns ns S 
 
 
ns- Not Significant 
S  - Significant 
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RECEIVER OPERATING CHARACTERISTIC  
CURVE FOR LDL 
 
Figure 1 
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RECEIVER OPERATING CHARACTERISTIC CURVE FOR 
LDL/HDL ratio 
 
Figure 2 
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RECEIVER OPERATING CHARACTERISTIC CURVE FOR 
TOTAL CHOLESTEROL/ HDL ratio 
 
Figure 3 
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RECEIVER OPERATING CHARACTERISTIC CURVE  
FOR hs CRP 
 
Figure 4              
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DISCUSSION 
Epidemiological and Clinical studies have shown strong 
relationship between markers of inflammation and the risk of future 
cardiovascular events. Inflammation can be detected locally by 
temperature and pH changes. It can be detected systemically by 
measurement of inflammatory markers. 
The markers of inflammation reported so far in atherosclerosis 
include high sensitivity C reactive protein, interleukin-6, serum amyloid 
A, tumour necrosis factor- alpha, soluble intercellular adhesion 
molecule-1, macrophage inhibitory cytokine-1, p- Selectin, CD40 
ligand.46, 47 
          Among these various markers, high sensitivity C- reactive protein 
is widely studied experimentally and is easy to estimate in the 
laboratory. It has been shown in the Honolulu heart study, that the 
measurement of high sensitivity C- reactive protein can be used to 
identify the risk of coronary artery disease at a very early stage.48 
          The traditional risk factors used in the prediction of 
atherosclerosis are low density lipoprotein cholesterol, triacylglycerol, 
total Cholesterol, LDL/HDL ratio, while high density lipoprotein is a 
marker of anti atherogenic potential in an individual. 
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          But the efficacy of these traditional risk factors is questionable in 
their ability to identify all the individuals at an increased risk. This has 
been shown in a 2003 study of more than 120,000 patients that 
approximately 20 percent of all coronary events occurred in the absence 
of any major risk factors like hyperlipidemia, hypertension, diabetes and 
smoking.49 
           In the present study, the mean value of hs- CRP showed a 
significant increase in the study group compared to the control group. 
The results of the present study shows a rise up to 2 fold in the levels of 
hs- CRP, which is consistent with the data given by Paul M. Ridker and 
James willerson, who documented a 1.5 to 7 fold increase of hs- CRP in 
patients with symptomatic atherosclerosis.14 
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SCATTER DIAGRAM OF hs- CRP LEVELS IN STUDY AND 
CONTROL GROUP      
0
1
2
3
4
5
6
7
8
9
0 10 20 30 40 50 60
control
study
 
The control group data obtained in the present study showed that 
35 out of 50 patients have hs- CRP levels in the range of 1-3 mg/L 
which is included in the moderate cardiovascular risk group by AHA/ 
CDC panel.44 
           This data coincides with the results of Li Pu, Ru Zhang et al. 
They have reported that hs- CRP is an independent biomarker for 
predicting coronary artery disease in diabetic population. In their follow 
up study the incidence of fatal cardiovascular events were much higher 
in patients who had hs- CRP in the levels of moderate to high 
cardiovascular risk group.50 
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Hence the patients taken as control group for the present study on 
the basis of normal ECG findings have to be evaluated by other tests to 
assess the cardiac function and must be followed up. 
          As both the groups in the present study are diabetics, the mean 
differences in the values of fasting plasma glucose concentration 
between the control and study groups are not significant. The values also 
reveal that the present study group subjects are well controlled diabetics. 
          The mean value of low density lipoprotein cholesterol in the study 
group is 131.32. The LDL goal for the patients with multiple risk factors 
(i.e) age> 45 years, male gender in the present study, according to 
National Cholesterol Education Program (NCEP) expert committee is 
less than 130, to reduce the risk of a major coronary event. 
          The study group has low density lipoprotein levels only slightly 
above the cutoff range. Rather than changes in the concentration of the 
low density lipoprotein, functional defects of low density lipoprotein, 
namely formation of small, dense low density lipoprotein would have 
occurred in the study group. These molecules are pro atherogenic. They 
could have predisposed the study group population to their present 
disease condition. 
           The Adult Treatment Panel III (ATPIII) classifies less than 
40mg/dL HDL Cholesterol as low and more than 60mg/dL HDL 
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Cholesterol as high. The mean value of HDL- C in the present study 
group is 33.30, which is classified as low HDL- C. The LDL/HDL ratio, 
which is an indicator of atherogenic potential, is significantly raised in 
the study group, and it is due to a decrease in the HDL levels, which 
could have predisposed the study group population to the coronary 
artery disease. More over functional defects in the HDL-C is more 
common in diabetics leading to decreased capacity to prevent the 
oxidation of LDL Cholesterol, promoting atherosclerosis.27  
         The mean value of Total Cholesterol/ HDL-C ratio in the study 
group is 5.91. Paul M. Ridker in his study has reported Total 
Cholesterol/ HDL-C ratio of more than 5.5 in men and 5.9 in women, 
strongly correlate with incident cardiovascular disease. Since the value 
of Total Cholesterol/ HDL-C ratio is one of the strongest predictors of 
cardiovascular risk, the high value of Total Cholesterol/ HDL-C ratio in 
the present study is consistent with the previous studies.47 
         As all the patients taken for the study were diabetics, the mean 
difference between the values of total Cholesterol in the control and 
study groups did not show any statistical significance. The mean value 
of triacylglycerol in the study group is 158.90, which is more than the 
cutoff proposed by ATP III as 150 mg/dL. Hence the changes in the 
lipoprotein concentration with its functional abnormalities due to 
diabetes could have predisposed to coronary artery disease. It was found 
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that most of the patients taken for the study were aware of the dietary 
control of the lipids and exercise for their ailment. This is probably one 
reason for the lipid levels in the study group being very close to the 
control. 
          The difference in the age matched study group did not show a 
uniform significance in any of the measured parameters except hs-CRP. 
This is probably because of the small number of patients taken for the 
study. 
          The Receiver Operating Characteristic Curves of the lipid 
parameters low density lipoprotein, LDL/HDL ratio, Total Cholesterol/ 
HDL ratio and hs-CRP reveal that the hs-CRP assay curve is above the 
assay curves of the lipid profile at all the points. Hence hs-CRP is a 
better assay for predicting the Cardio vascular risk.  
In the Pearson’s Correlation analysis, there is a significant 
correlation noticed between hs- CRP and LDL/HDL ratio. Since there is 
no significant linear correlation between hs- CRP and other lipid 
parameters, the risk of cardiovascular disease can be calculated by the 
algorithm proposed by Rifai N and Ridker employing the cutoff values 
of LDL and hs-CRP as proposed by NCEP panel.51  
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Proposed algorithm for risk assessment of coronary heart 
disease in men and women
 
         The prognostic additive effect of hs- CRP to the lipid screen is 
very useful in the diabetic population, because the relative risk in these 
patients can be calculated and the patients on moderate to high risk 
group can be diagnosed earlier, because most diabetic individuals do not 
exhibit classical anginal symptoms. 
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CONCLUSION 
High Sensitivity C- reactive protein is useful as a marker for 
atherosclerotic Coronary artery disease in Diabetes mellitus. Any patient 
with increased High Sensitivity C- reactive protein levels must be 
investigated for atherosclerotic Coronary artery disease. 
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SCOPE FOR FUTURE STUDY 
Tissue necrosis is a potent acute phase stimulus, and, following 
myocardial injury, there is a major CRP response and the magnitude of 
this response, reflects the extent of myocardial necrosis. C-reactive 
protein can also be used to predict the outcome after myocardial 
infarction. 
CRP is co -deposited with activated complement within all 
myocardial infarct and CRP response reflects not only the tissue 
damage, but may also contribute to the severity of ischaemic myocardial 
injury. 
           If these observations are confirmed, measurement of CRP may 
become an indication for prophylactic anti atherosclerotic therapy in 
apparently low risk individuals. 
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MASTER CHART FOR CONTROL GROUP 
S.No Age Group Glucose (mg/dL) 
Total 
Chol 
(mg/dL) 
Trig 
(mg/dL) 
HDL 
(mg/dL) 
LDL 
(mg/dL) 
VLDL 
(mg/dL) 
TC/HDL 
Ratio 
LDL/HDL 
Ratio 
Hs- 
CRP 
(mg/L) 
1 47 1 110 145 72 59 72 14 2.45 1.22 0.78 
2 45 1 96 161 255 46 64 51 3.5 1.39 1.28 
3 50 1 126 190 256 46 93 51 4.13 2.02 2.15 
4 54 1 85 156 270 42 59 54 3.71 1.40 1.77 
5 45 1 139 150 86 35 46 18 4.28 1.31 0.43 
6 45 1 116 148 126 51 50 25 2.90 0.98 1.77 
7 60 1 153 181 283 33 92 56 5.48 2.78 2.82 
8 45 1 98 154 155 49 74 31 3.14 1.51 1.45 
9 60 1 86 171 165 45 93 33 3.80 2.06 1.21 
10 45 1 112 167 141 47 92 28 3.55 1.95 1.87 
11 54 1 180 200 128 58 120 22 3.44 2.06 1.21 
12 48 1 162 175 100 42 113 20 4.16 2.69 0.66 
13 51 1 77 142 132 32 83 26 4.43 2.59 1.91 
14 49 1 92 173 145 30 114 29 5.76 3.80 1.70 
15 46 1 176 181 127 30 125 25 6.03 4.16 2.33 
16 55 1 202 284 364 38 173 73 7.47 4.55 3.52 
17 65 1 138 151 200 25 86 40 6.04 3.44 2.82 
18 46 1 96 111 78 37 58 16 3.00 2.14 0.98 
19 53 1 85 190 111 33 135 22 5.75 4.09 1.56 
20 58 1 140 192 115 36 133 23 5.33 3.69 1.35 
21 51 1 120 171 122 40 107 24 4.27 2.67 1.38 
22 49 1 110 190 105 30 139 21 6.33 4.63 2.61 
23 47 1 106 188 98 53 115 20 3.54 2.16 1.17 
24 51 1 102 159 65 38 108 13 4.18 2.84 0.47 
25 54 1 88 176 115 52 101 23 3.38 1.94 2.26 
26 63 1 96 194 114 42 130 23 4.61 3.09 1.73 
27 66 1 110 216 124 47 144 25 4.59 3.06 1.94 
28 70 1 106 138 116 40 75 23 3.45 1.87 1.45 
29 54 1 116 106 151 22 53 30 4.81 2.40 1.21 
30 51 1 98 135 156 32 72 31 4.21 2.25 1.94 
31 58 1 256 158 262 23 83 52 6.86 3.60 4.12 
32 51 1 76 173 97 24 130 19 7.20 5.41 0.98 
33 63 1 151 170 111 40 107 22 4.20 2.67 1.01 
34 61 1 103 226 127 38 163 25 5.90 4.28 2.47 
35 58 1 112 178 141 24 126 28 7.41 5.25 2.33 
36 51 1 121 127 150 25 72 30 5.08 2.88 1.59 
37 54 1 108 158 133 39 92 27 4.05 2.35 1.35 
38 58 1 116 264 143 43 192 29 6.13 4.46 2.82 
39 49 1 228 299 144 51 219 29 5.86 4.29 1.87 
40 54 1 130 179 160 31 116 32 5.77 3.74 1.35 
41 57 1 112 260 133 41 92 27 6.34 2.24 3.22 
42 49 1 169 176 176 20 121 35 8.80 6.05 1.09 
43 48 1 96 258 114 39 196 23 6.60 5.02 1.87 
44 56 1 88 160 90 39 103 18 4.10 2.64 0.58 
45 51 1 61 284 364 38 173 73 7.47 4.55 2.75 
46 51 1 100 136 113 34 79 23 4.00 2.32 1.21 
47 49 1 120 141 115 43 75 23 3,27 1.74 1.28 
48 47 1 116 171 122 40 107 24 4.27 2.67 2.40 
49 49 1 141 173 145 30 114 29 5.76 3.80 1.80 
50 53 1 108 156 130 32 98 26 4.87 3.06 1.63 
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MASTER CHART FOR CASE GROUP 
S.No Age Group Glucose (mg/dL) 
Total 
Chol 
(mg/dL)
Trig 
(mg/dL)
HDL 
(mg/dL)
LDL 
(mg/dL)
VLDL 
(mg/dL)
TC/HDL
Ratio 
LDL/HDL 
Ratio 
Hs- CRP 
(mg/L) 
1 65 2 128 166 134 22 117 27 7.54 5.31 4.72 
2 62 2 136 176 176 20 121 35 8.80 6.05 5.74 
3 59 2 112 141 125 22 94 25 6.40 4.27 5.87 
4 66 2 96 203 120 40 139 24 5.07 3.47 6.18 
5 59 2 136 201 165 33 135 33 6.09 4.09 6.00 
6 55 2 210 189 119 33 132 24 5.72 4.00 6.67 
7 49 2 166 194 134 37 130 27 5.24 3.51 7.24 
8 55 2 138 117 136 22 68 27 5.31 3.09 6.71 
9 59 2 102 136 136 33 76 27 4.12 2.30 7.68 
10 61 2 116 264 143 43 192 29 6.13 4.46 6.89 
11 67 2 100 241 133 31 183 27 7.77 5.90 6.75 
12 68 2 148 299 144 51 219 29 5.86 4.29 7.06 
13 66 2 134 213 132 46 141 26 4.63 3.06 7.46 
14 53 2 121 144 137 26 91 27 5.53 3.50 6.44 
15 51 2 116 151 123 27 99 25 5.59 3.66 6.53 
16 49 2 122 226 127 38 163 25 5.94 4.28 7.28 
17 69 2 172 179 160 31 116 32 5.77 3.74 6.00 
18 58 2 280 189 119 22 143 24 8.59 6.50 7.15 
19 49 2 154 135 145 33 73 29 4.09 2.21 8.08 
20 46 2 108 205 101 37 148 20 5.54 4.00 6.84 
21 63 2 86 177 134 30 120 27 5.90 4.00 5.91 
22 58 2 94 158 133 39 92 27 4.05 2.35 4.99 
23 58 2 102 260 133 41 192 27 6.34 4.68 5.30 
24 44 2 124 238 139 30 180 28 7.93 6.00 6.18 
25 53 2 138 178 141 24 126 28 7.41 5.25 7.06 
26 60 2 180 170 111 40 108 22 4.25 2.70 5.16 
27 55 2 102 127 150 25 72 30 5.08 2.88 6.67 
28 66 2 130 170 111 40 108 22 4.25 2.70 7.68 
29 70 2 120 174 119 21 129 24 8.28 6.14 6.71 
30 60 2 88 188 115 25 140 23 7.52 5.60 5.21 
31 45 2 116 144 137 26 91 27 5.53 3.50 5.12 
32 53 2 96 188 115 25 140 23 7.52 5.60 6.00 
33 58 2 134 227 114 41 163 23 5.53 3.97 6.75 
34 48 2 121 200 117 36 141 23 5.50 3.91 6.71 
35 59 2 110 222 126 33 164 25 6.72 4.96 6.97 
36 47 2 98 151 103 36 94 21 4.19 2.61 7.77 
37 54 2 102 192 115 36 133 23 5.33 3.69 8.30 
38 60 2 96 185 122 36 125 24 5.13 3.47 8.08 
39 45 2 169 189 180 22 131 36 8.59 3.63 8.52 
40 60 2 108 202 104 52 129 21 3.88 2.48 7.11 
41 49 2 141 216 124 47 144 25 4.59 3.06 5.74 
42 58 2 86 176 137 36 112 27 4.88 3.11 6.84 
43 59 2 126 192 106 34 137 21 5.64 4.02 7.59 
44 57 2 114 178 124 40 113 25 4.45 2.82 6.97 
45 66 2 110 258 114 39 196 23 6.61 5.02 6.93 
46 63 2 108 180 126 30 125 25 6.00 4.16 6.71 
47 61 2 126 192 119 27 141 24 7.11 5.22 5.25 
48 61 2 102 188 114 25 140 23 7.52 5.60 5.12 
49 55 2 124 172 113 41 108 23 4.19 2.63 5.91 
50 60 2 129 260 133 41 192 27 6.34 4.68 3.39 
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PROFORMA 
Stanley Medical College, 
Chennai. 
 
NAME :                                                                             CASE NO : 
 
AGE/ SEX :                                                                       OP/ IP NO: 
 
H/O Presenting illness : 
 
 
 
 
 
Past history ; 
 
 
 
Examination : 
 
Height :                              Weight 
 
Heart rate :                          BP: 
 
Respiratory rate : 
 
Cardiovascular system :                                              Respiratory system: 
 
 
Central nervous system:                                              Abdomen: 
 
 
Investigations: 
 
Blood Sugar: 
 
Lipid profile: 
                Total Cholesterol 
                High density lipoprotein 
                Triglycerides 
                Calculated: Very low density lipoprotein, Low density lipoprotein. 
 
High sensitivity C- reactive protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serum lipoprotein fractions showing lipid composition and apoprotein 
components. Binding of lipoproteins to receptors is mediated through 
apoproteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pathogenesis of atherosclerosis. 1, chronic endothelial injury leads to 2.2,Endothelial 
dysfunction, permeability, and inflammation.  3, Activated  monocytes infiltrate the arterial 
wall and smooth muscle proliferates.4, Macrophages engulf lipid to become foam cells. 5, A 
lipid core forms in the arterial wall and fibrous cap evolves. 
